Research peptide targeting GLP-1 and GIP pathways for weight loss

Product overview

Tirzepatide is an investigational dual incretin receptor agonist designed to target both GLP-1 and GIP signaling pathways. This dual-receptor profile places it between traditional GLP-1 analogues and newer multi-agonist compounds, making it a central reference point in modern metabolic research.
By engaging two key hormonal pathways involved in nutrient signaling and energy balance, Tirzepatide is widely studied in experimental models focused on appetite regulation, glucose metabolism, and systemic energy homeostasis. Its mechanism provides a broader signaling profile compared to single-pathway GLP-1 compounds, while remaining more selective than triple agonists such as Retatrutide.
Researchers often use Tirzepatide as a benchmark compound when comparing single, dual, and multi-receptor incretin strategies. For a deeper comparison across these classes, see the GLP-1 metabolic research guide.

Research applications (investigational)

Tirzepatide has been investigated in preclinical and experimental settings for its involvement in:

Dual incretin receptor signaling (GLP-1 and GIP pathways)
Glucose metabolism and insulin signaling dynamics
Appetite regulation and satiety-related signaling mechanisms
Energy balance and metabolic pathway modulation
Hepatic and lipid metabolism signaling pathways
Comparative analysis of single vs dual incretin receptor activation

These areas reflect ongoing scientific investigation into metabolic signaling systems rather than established applications.

Product characteristics

Purity: ≥99% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: 4813.45
Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Storage: store lyophilized powder at -20°C, protect from light and moisture. Reconstituted solution should be kept at 2–8°C and used within a short period.

Independent third-party verification

This batch has undergone additional third-party analytical verification through Janoshik Analytical
Batch: TR10-260423
Internal HPLC purity: 99.13%
Third-party verification: 99.62% independently confirmed high purity and identity consistency. View third-party verification.

Why choose our Tirzepatide?

≥ 99% purity verified by HPLC.
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Reconstitution: Must be reconstituted with bacteriostatic water before use. GLP-1 class peptides are sometimes slow to dissolve and require very gentle reconstitution to avoid foaming or remaining slightly cloudy.

Selected research references

Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022.
Frias JP et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2021.
Ludvik B et al. “Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin.” The Lancet, 2021.
Coskun T et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.” Molecular Metabolism, 2018.
ClinicalTrials.gov Identifier: NCT04184622 — Tirzepatide research in obesity and metabolic signaling pathways.

Related research context

Tirzepatide is part of the dual incretin receptor agonist (GLP-1/GIP) metabolic research class. For mechanistic comparison with single-pathway GLP-1 agonists and triple-agonist compounds, see our GLP-1 metabolic research guide.

Browse all compounds in the Metabolic research category.

Researchers comparing multi-receptor activation may also examine:

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

Dualer Agonist

Tirzepatid 10 mg